Hemostemix Inc. (CVE:HEM – Get Free Report) shares fell 17.1% during mid-day trading on Wednesday . The stock traded as low as C$0.28 and last traded at C$0.32. 605,102 shares were traded during trading, a decline of 10% from the average session volume of 669,888 shares. The stock had previously closed at C$0.38.
Hemostemix Stock Performance
The company has a 50 day moving average of C$0.15 and a 200-day moving average of C$0.10. The stock has a market cap of C$27.01 million, a price-to-earnings ratio of -15.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Most active stocks: Dollar volume vs share volume
- Nebius Group: Market Overreaction or Real AI Disruption?
- What is a Stock Market Index and How Do You Use Them?
- The Best Way to Invest in Gold Is…
- What is the Dow Jones Industrial Average (DJIA)?
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
